Pliant Therapeutics, Inc. (PLRX)

Market Cap	71.21M -15.3%
Revenue (ttm)	n/a
Net Income	-113.22M
EPS	-1.84
Shares Out	61.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	409,113
Open	1.160
Previous Close	1.170
Day's Range	1.130 - 1.180
52-Week Range	1.090 - 1.950
Beta	1.21
Analysts	Hold
Price Target	2.67 (+132.17%)
Earnings Date	May 11, 2026

About PLRX

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX
• Website: https://pliantrx.com

Analyst Summary

According to 6 analysts, the average rating for PLRX stock is "Hold." The 12-month stock price target is $2.67, which is an increase of 132.17% from the latest price.

Price Target

$2.67

(132.17% upside)

Analyst Consensus: Hold